2024-09-24 - Analysis Report
## Vertex Pharmaceuticals Inc. (VRTX) Stock Analysis Report

**Company Overview:** Vertex Pharmaceuticals Inc. is a biotechnology company focused on developing and commercializing therapies for serious diseases.

**Performance Analysis:**

**1. Outperformance vs. S&P 500:**

* VRTX has accumulated a total return of 170.91% compared to 132.53% for the S&P 500 (VOO). 
* The current outperformance is 38.38%, indicating VRTX has outperformed the benchmark by a significant margin. 
* The relative outperformance is 73.35%, placing VRTX within the top 73.35% of its historical performance against the S&P 500. 

**2. Recent Price Movements:**

* **Closing Price:** $464.92
* **5-Day Moving Average:** $477.9
* **20-Day Moving Average:** $479.21
* **60-Day Moving Average:** $481.84

VRTX is currently trading below its 5-day, 20-day, and 60-day moving averages, indicating a downward trend.

**3. Technical Indicators:**

* **RSI:** 32.83
* **PPO:** -0.15
* **Delta_Previous_Relative_Divergence:** -8.95 (Short-term downward trend)
* **Expected_Return:** 21.45% (5-year expected return)

The RSI indicates that VRTX is currently in oversold territory, but the negative PPO and Delta_Previous_Relative_Divergence suggest a short-term downtrend. However, the expected return is positive, indicating potential future growth.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-02 | -13.92 | 2.65 B$ |
| 2024-05-07 | 4.26 | 2.69 B$ |
| 2023-11-07 | 4.01 | 2.48 B$ |
| 2023-08-02 | 3.55 | 2.49 B$ |
| 2024-08-02 | 3.55 | 2.49 B$ |

The most recent earnings report (2024-08-02) showed a significant decline in EPS, which could explain the recent downtrend in the stock price. However, the revenue remains stable. It's important to consider the earnings call transcript and analyst expectations to get a better understanding of the company's outlook.

**5. Summary:**

VRTX has historically outperformed the S&P 500. Currently, the stock is trading below its moving averages and experiencing a short-term downtrend. Despite the recent earnings miss, the long-term expected return remains positive. The company is facing challenges in the short term, but its long-term growth potential remains promising. It's crucial to monitor the company's future earnings releases and any changes in its strategic direction to assess its future performance. 
